株探米国株
英語
エドガーで原本を確認する
0001040130FALSE00010401302024-04-292024-04-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 29, 2024
PetMed Express, Inc.
(Exact name of registrant as specified in its charter)
Florida
000-28827
65-0680967
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
420 South Congress Avenue, Delray Beach, Florida 33445
(Address of principal executive offices) (Zip Code)
(561) 526-4444
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $.001 per share
PETS
NASDAQ
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
Exchange Act. o




Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Transition and Separation Agreement with Mathew Hulett

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the On April 29, 2024, PetMed Express, Inc. (the “Company”) and Mathew Hulett entered into a Transition and Separation Agreement pursuant to which Mr. Hulett resigned as President and Chief Executive Officer, and also as a director, of the Company effective April 29, 2024 (the “Separation Agreement”). Under the terms of the Separation Agreement, Mr. Hulett will remain employed by the Company through May 10, 2024 to assist the Company in transition matters, and the Company will pay Mr. Hulett severance compensation thereafter in the form of the continuation of his base salary and reimbursement of COBRA premiums through August 30, 2024, which was the scheduled expiration date of his employment agreement. The Separation Agreement also provides that the Company will accelerate the vesting of Mr. Hulett’s remaining unvested shares of restricted common stock (consisting of 30,000 shares) previously granted under a Restricted Stock Agreement between the Company and Mr. Hulett. Mr. Hulett has agreed to a general release and waiver of claims against the Company as a condition receiving the foregoing amounts, and he has agreed to provide the Company, on an as-needed and as-requested basis, such consulting services as the Company may from time to time reasonably request, up to a maximum of five hours during each calendar week, through August 30, 2024.

Appointment of Sandra Campos as CEO; Executive Employment Agreement with Ms. Campos

On April 29, 2024, the Company appointed Sandra Campos, an existing director of the Company, as the Company’s new Chief Executive Officer and President. On the same date, the Company and Ms. Campos entered into an Executive Employment Agreement setting forth the terms under which Ms. Campos will be employed by the Company as Chief Executive Officer and President (the “Employment Agreement”). Ms. Campos will continue to serve as a director of the Company for so long as she remains Chief Executive Officer and President.

Ms. Campos, age 57, has served as a member of the Company’s board of directors since May 17, 2023, and a member of the Audit, Compensation, and Corporate Governance and Nominating committees from May 17, 2023 to April 29, 2024. Ms. Campos served as the chief executive officer of DVF (Diane von Furstenberg), a luxury fashion brand, from April 2018 to November 2020. Prior to joining DVF, Ms. Campos was the co-president, Women’s Apparel, of Global Brands Group Holding Limited (a branded apparel, footwear and brand management company) from 2015 to April 2018, which included the Juicy Couture, Bebe, Buffalo, Tretorn, BCBG and Herve Leger brands. Ms. Campos also has held leadership roles prior thereto with apparel companies Polo Ralph Lauren and Nautica International. Ms. Campos also founded Fashion Launchpad (a continuing education platform for retail and fashion professionals) in June 2020, and created Dream out Loud in partnership with Selena Gomez (the first teen celebrity brand management company) which was established in 2009, and launched at retail in 2010. After her departure from DVF, Ms. Campos served as the chief executive officer of Project Verte Inc. (a retail technology and supply chain solutions provider) from November 2020 until November 2021. A receivership proceeding was filed against Project Verte Inc. in August 2022 in the Delaware Court of Chancery. The receiver subsequently filed a bankruptcy proceeding under Chapter 7 of the U.S. Bankruptcy Code with respect to Project Verte Inc. in January 2023 in the U.S. Bankruptcy Court for the District of Delaware. Ms. Campos has been a member of the board of directors of Big Lots (NYSE:BIG), and a member of its audit committee and capital allocation planning committee since May 2021, as well as a director of various private companies.

Ms. Campos’ Employment Agreement provides for an initial employment term of 3 years and for automatic renewal for successive 1-year terms thereafter unless either party provides notice of nonrenewal at least 60 days prior to the end of the then-current term. As provided in the Employment Agreement, Ms. Campos will serve the Company on a full-time basis and will receive an annual base salary of $550,000, which may be increased in the discretion of the board of directors (but may not be decreased other than as part of a proportionate reduction in management salaries and wages applicable to all senior management). Ms. Campos will receive a signing bonus of $120,000, which is subject to repayment if Ms. Campos leaves the Company within one year under circumstances detailed in the Employment Agreement. Ms. Campos will also receive customary expense reimbursement (in accordance with the Company’s standard policies), and will receive the medical, health, and other benefits provided to Company employees generally, including participation in the Company’s 401(k) plan on the same basis as other employees generally. The Employment Agreement provides that Ms. Campos will be eligible to receive an annual performance bonus based on annual performance goals determined by the Company’s board of directors, with a target annual bonus of 100% of Ms. Campos’ base salary and a maximum bonus of 200% of base salary. The agreement includes customary restrictive covenants, including confidentiality and non-solicitation covenants and a one-year post-employment non-compete restriction.

Under the Employment Agreement, Ms. Campos will be entitled to equity grants under the Company’s current or future equity plan, as follows: On April 29, 2024, Ms. Campos will receive a grant of restricted stock units (“RSUs”) under the Company’s 2022 Employee Equity Compensation Plan for a number of RSUs equal to $2.0 million divided by the closing price of the Company’s common stock on the Nasdaq Stock Market on the date of grant.
2


Such RSUs will vest in one-third increments on each of the first 3 anniversaries of the date of grant so long as Ms. Campos continues to be employed by the Company on each vesting date, and such RSUs will otherwise contain the standard provisions for RSU grants by the Company. Thereafter, Ms. Campos will be entitled to annual grants of RSUs and performance stock units (“PSUs”) having an aggregate value per grant of $750,000 for the annual RSU grant and $750,000 for the annual PSU grant, with such value being calculated based on the closing price of the Company’s common stock on the date of grant but subject to a floor of $4.00 per share. The RSUs included in any such annual grants will vest in the same manner as the initial RSU grant, and the PSUs will have a 3-year performance period and such performance goals and other terms as shall be determined by the Company’s board of directors.

The Employment Agreement provides that Ms. Campos’ employment may be terminated by either the Company or Ms. Campos at any time prior to the scheduled expiration date of the agreement, subject to notice requirements and subject to certain potential severance payment obligations based on the nature of the termination. Specifically, Ms. Campos’ employment may be terminated by the Company with or without “Cause” (as defined in the Employment Agreement) or by Ms. Campos with or without “Good Reason” (as defined in the Employment Agreement). “Cause” is customarily defined to include a material breach of the Employment Agreement, commission of a felony, and certain types of dishonesty and misconduct, all as more particularly defined in the Employment Agreement. “Good Reason” includes certain material adverse changes in Ms. Campos’ duties, responsibilities, functions or title with the Company or a material breach of the Employment Agreement by the Company, as more particularly defined in the Employment Agreement.

In the event that the Company terminates Ms. Campos’ employment without Cause or determines not to renew the Employment Agreement upon expiration, or Ms. Campos resigns for Good Reason in the manner described or required in the Employment Agreement, the agreement provides that Ms. Campos will be entitled to receive, contingent on Ms. Campos delivering a general release of claims to the Company, severance compensation in the form of continuation of her base salary in effect at the time of termination, as well as reimbursement for COBRA premiums, for a period of 12 months after termination. If such termination of employment occurs during the 12-month period following a “Change of Control” (as defined in the Employment Agreement), then Ms. Campos would be entitled to receive, contingent on delivery of a general release to the Company, severance compensation in the form of continuation of her base salary in effect at the time of termination and reimbursement for COBRA premiums for a period of 24 months (or 18 months for COBRA reimbursement) after termination, and she will also be entitled to receive a pro rata amount of her target bonus for the year of termination, accelerated vesting of all unvested RSUs then held by her, and vesting of unvested PSUs then held by her in the manner specified in the Employment Agreement.


* * *

The foregoing does not purport to be a complete description of the Separation Agreement and the Employment Agreement and is qualified in its entirety by reference to the full text of such agreements, which are attached as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.




Item 7.01 Regulation FD Disclosure

On April 29, 2024, the Company issued a press release announcing the appointment of Ms. Campos as Chief Executive Officer and President of the Company and the departure of Mr. Hulett. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 7.01 and the related information in Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference in any filing made by the Company under the Securities Act or the Exchange Act except as set forth by specific reference in such filing.
3


Item 9.01 Financial Statements and Exhibits.

(d)    Exhibits
Exhibit No.
Description
10.1
10.2
99.1
104
Cover Page Interactive Data File (formatted as Inline XBRL)


* * *
4


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 29, 2024
PETMED EXPRESS, INC.
By: /s/ Christine Chambers
Name: Christine Chambers
Title: Chief Financial Officer and Treasurer
5
EX-10.1 2 pets-20240429xexx101.htm EX-10.1 Document

EXHIBIT 10.1

TRANSITION AND SEPARATION AGREEMENT

THIS TRANSITION AND SEPARATION AGREEMENT (this “Agreement”) is dated as of April 29, 2024 (the “Effective Date”), by and between MATHEW HULETT, an individual whose address is 7044 54th Ave NE, Seattle, WA 98115 (“Executive”), and PETMED EXPRESS, INC., a Florida corporation whose principal place of business is located at 420 South Congress Avenue, Delray Beach, FL 33445 (the “Company”). The Company and Executive are sometimes individually referred to in this Agreement as a “Party” and collectively as the “Parties.”

RECITALS

A.Executive is currently employed by the Company as the Company’s Chief Executive Officer and President and, in connection therewith, the Company and Executive are parties to an Executive Employment Agreement, dated August 25, 2021 (the “Employment Agreement”).

B.Executive and the Company have agreed that Executive will resign as the Chief Executive Officer and President of the Company and, thereafter will provide advisory services to the Company on the terms and conditions described in this Agreement.

NOW THEREFORE, in consideration of the mutual promises set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows:

TERMS
1.Recitals. The foregoing Recitals are true and correct and are incorporated into this Agreement.

2.Termination of Employment. Executive and the Company agree that Executive’s employment with the Company will terminate as of the close of business on May 10, 2024 (the “Employment Termination Date”). In addition, as of the Employment Termination Date, the Employment Agreement shall terminate in full, and Executive will have no further rights and the Company will have no further obligations thereunder, provided, however, that the termination of the Employment Agreement shall not affect (i) Executive’s obligations under Section 9 the Employment Agreement, which shall remain in full force and effect after the Employment Agreement in accordance with the terms and provisions of the Employment Agreement (the “Continuing Obligations”), subject to Section 10 of the Employment Agreement, (ii) Executive’s indemnification rights (and the Company’s corresponding indemnification obligations) pursuant to and in accordance with (A) the Indemnification Agreement, dated December 27, 2022, between Executive and the Company (the “Indemnification Agreement”), (B) the indemnification provisions of Sections 607.0850 through 607.0859 of the Florida Business Corporation Act, and (C) Article 9 of the Company’s Second Amended and Restated Bylaws (collectively, the “Indemnification Rights”). After the Employment Termination Date, Executive will not represent himself as being an employee, officer, agent, or representative of the Company. While Executive will remain an employee of the Company through the Employment Termination Date, Executive hereby confirms his resignation, as of the Effective Date, from the offices of Chief Executive Officer and President of the Company, as a director of the Company, and from all other offices, directorships, manager positions, trusteeships, committee memberships and fiduciary and other capacities held with, or on behalf of, the Company and its subsidiaries, and Executive’s execution of this Agreement will be deemed the grant by Executive to the officers of the Company of a limited power of attorney to sign in Executive’s name and on Executive’s behalf any such documentation as may be required to be executed solely for the limited purposes of effectuating such resignations.

3.Obligations Prior to Employment Termination Date; Post-Termination Consulting Services; Cooperation and Assistance.

a.Executive agrees that, during the period of time from the date of this Agreement through the Employment Termination Date, Executive shall continue to perform his duties to the Company on a full-time basis (and not take vacation or paid-time off) and will use his best efforts to help facilitate a smooth transition of his functions and duties to his successor or other employees of the Company, including without limitation providing such transition assistance as shall be reasonably requested by the Company and/or the Executive’s successor.



b.In consideration of and as an inducement to the Company entering into this Agreement when not otherwise obligated to do so, Executive agrees that he will, during the period commencing on the Employment Termination Date and through and including August 30, 2024 (the “Consulting Period”), provide the Company, on an as-needed and as-requested basis, such consulting services as the Company may from time to time reasonably request relating to matters that were within the purview of Executive’s role and duties to the Company during his employment (the “Consulting Services”), up to a maximum of five (5) hours of Consulting Services during each calendar week during the Consulting Period. The Consulting Services shall be rendered remotely and may include, without limitation and at the request of the Company, being available by email, through internet connection, and by telephone during normal business hours during ordinary business days, to answer questions and provide information and assistance relating to, and to otherwise cooperate with the Company and its management with respect to, transitional matters and other matters that Executive was involved with during the term of his employment with the Company. The Consulting Services shall be rendered for no additional compensation other than payment of the Severance Compensation described below.
c.In addition to the Consulting Services, Executive agrees that he will, without any additional compensation, at all times following the Employment Termination Date provide reasonable cooperation to the Company and/or its affiliates and its or their respective counsel in connection with any investigation, administrative proceeding or litigation relating to any matter that occurred during Executive’s employment in which Executive was involved or of which Executive has knowledge. The Company agrees to reimburse Executive for reasonable out-of-pocket expenses incurred at the request of the Company with respect to this Section 3.c.

4.Accrued Compensation and Severance Compensation. Executive agrees that the only employment compensation to which Executive will be entitled after the Employment Termination Date will be (i) any earned but unpaid Base Salary (as defined in the Employment Agreement) through the Employment Termination Date (the “Accrued Compensation”), and (ii) cash severance compensation in the aggregate amount of $159,614 (the “Severance Amount”). The Severance Amount will be paid in equal installments during the period from the Employment Termination Date through August 30, 2024, in accordance with the Company’s regular payroll schedule and subject to normal and required tax and other withholdings; provided, however, that payments of the Severance Amount will not commence until expiration of the Revocation Period and only if Executive does not exercise his revocation rights under Section 19 and 20 below, and the Company will have the right to terminate such payments in the event that Executive materially breaches this Agreement or the Continuing Obligations, but only after having first provided Executive written notice of said alleged material breach and allowing Executive ten (10) business days thereafter to cure said alleged material breach.

5.Outstanding Equity Awards. The Parties acknowledge that the Company and Executive are currently parties to (i) a Restricted Stock Agreement, dated August 30, 2021 (the “RSA Agreement”), pursuant to which Executive was granted 90,000 shares of restricted common stock of the Company (the “RSA Shares”) under the Company’s 2016 Employee Equity Compensation Restricted Stock Plan (the “Plan”) upon the terms and conditions set forth in the RSA Agreement and the Plan, of which 60,000 shares are vested and 30,000 shares are unvested as of the date of this Agreement (the “Unvested RSA Shares”), and (ii) a Restricted Performance Stock Agreement, dated August 20, 2021 (the “PSA Agreement”), pursuant to which Executive was granted 510,000 shares of restricted common stock of the Company (the “PSA Shares”) under the Plan upon the terms and conditions set forth in the PSA Agreement and the Plan, none of which shares have vested as of the date of this Agreement. Executive and the Company hereby agree that, upon the first day following the expiration of the Revocation Period and only if Executive has not revoked this Agreement pursuant to Section 19 and/or 20 below, all of the Unvested RSA Shares shall be deemed to become fully vested and the forfeiture restrictions with respect thereto shall be deemed to lapsed notwithstanding anything in the RSA Agreement or the Plan to the contrary. Executive and the Company hereby further agree and acknowledge that the forfeiture restrictions on the entirety of the PSA Shares have not lapsed, none of the PSA Shares have vested, all of the PSA Shares shall be deemed forfeited as of the date of this Agreement, and the PSA Agreement is hereby terminated. Executive acknowledges that, subject to the foregoing, he does not hold and is not entitled to any options, restricted shares, performance shares, restricted stock units, or other equity awards from the Company.



6.Survival of Certain Obligations; Updating of Social Media Accounts; Continuing Obligations under Securities Laws.

a.Notwithstanding the termination of Executive’s employment and the termination of the Employment Agreement, Executive agrees and acknowledges that all of the Continuing Obligations shall remain in full force and effect at all times hereafter (including after the Effective Date and Employment Termination Date).

b.Executive agrees that within five (5) business days following the Employment Termination Date, Executive will update his accounts or profiles on any social media platform (including, but not limited to, Facebook, X, or LinkedIn) to reflect that Executive is no longer employed by or affiliated with the Company (except that Executive may continue to state through August 30, 2024 that Executive is an advisor to the Company).

c.Executive acknowledges, understands, and agrees that: (i) for purposes of Rule 144 under the Securities Act of 1933, as amended, he will be deemed an “affiliate” of the Company for a period of ninety (90) days following the Effective Date, (ii) he may, following the Employment Date, continue to have certain obligations and liabilities under Section 16 of the Securities Exchange Act of 1934 Act, as amended, and Executive agrees to comply with the applicable provisions of said Section 16, (iii) Executive agrees to continue to be subject to the Company’s insider trading policy, including pre-clearance requirements, through August 30, 2024, and (iv) Executive may continue to be in possession of material nonpublic information regarding the Company for an indefinite period of time following the Employment Termination Date and that he will, in fact, be deemed to be in possession of material nonpublic information regarding the Company through at least the date on which the Company files its Annual Report on Form 10-K for the Company’s fiscal year ended March 31, 2024, and Executive agrees to comply with all laws, rules, and regulations regarding trading securities of an issuer while in possession of material nonpublic information of such issuer.

7.No Awareness of Certain Conduct. Executive represents that Executive is not aware of any conduct that Executive believes would constitute fraud, any accounting or financial improprieties, or any conduct that would be unlawful under applicable law. Executive agrees that Executive has not suffered any on the job injury for which Executive has not already filed a claim. In addition, the Company represents that its executive officers are not, as of the date of this Agreement, aware of any conduct by Executive that the Company believes would constitute fraud, any accounting or financial improprieties, or any conduct that would be unlawful under applicable law.

8.Releases and Waivers of Claims. In consideration for the payments and other benefits provided for under this Agreement, Executive hereby unconditionally and irrevocably releases, waives and forever discharges the Company and all past and present parents, successors in interests and assigns, affiliates, subsidiaries, divisions, departments, wholly-owned corporations or partnerships, business associations, sole proprietorships, insurers and its current or former officers, agents, representatives, attorneys, fiduciaries, administrators, directors, stockholders, members, partners, or employees, in both their individual and official capacities (herein collectively referred to as “Released Parties”) of and from, and agrees not to sue and not to assert against them any causes of action, claims and demands whatsoever, known or unknown, at law, in equity, or before any agency or commission of local, state and federal governments, arising, alleged to have arisen, or which might have been alleged to have arisen, or which may arise under any law, rule, or regulation, including, but not limited to, the Civil Rights Act of 1886, 1871, 1964, and 1991; 42 U.S.C. Section 1981; the Age Discrimination in Employment Act; the Equal Pay Act; the Employee Retirement Income Security Act; the Americans with Disabilities Act; the Family and Medical Leave Act; the National Labor Relations Act; the Fair Labor Standards Act, the Immigration Reform and Control Act of 1986; the Worker Adjustment Retraining and Notification Act; the Occupational Safety and Health Act; the Consolidated Omnibus Budget Reconciliation Act; the Florida Civil Rights Act of 1992; the Florida Minimum Wage Act; the Genetic Information Nondisclosure Act; the Florida Whistle-Blower’s Act; Sections 440.205 and 448.101-105, Florida Statutes; the Washington Industrial Welfare Act; the Washington Law Against Discrimination; the Washington leave laws; the Washington Minimum Wage



Requirements and Labor Standards Act; the Washington Equal Pay Opportunity Act; the Washington Fair Chance Act; and any other statutory, common law, or public policy claim, whether in tort (including without limitation any claim for assault, battery, intentional infliction of emotional distress, invasion of privacy, negligence, or negligent hiring, retention, or supervision) or contract including but not limited to any claims of any breach of any prior letters or employment agreements with the Company; whether federal, state, or local; whether at law or in equity; including attorney fees, costs, and expenses, to the date of this Agreement. Executive expressly intends this release to reach to the maximum extent permitted by law. Notwithstanding this provision, expressly excluded from this release, are any of the Company’s obligations to Executive pursuant to this Agreement.

EXECUTIVE understands that this Agreement releases all claims based on facts or omissions occurring on or before the date of this Agreement, even if executive does not, at the time executive signs this Agreement, have knowledge of those facts or omissions.

9.     Challenge to Enforceability. Executive agrees not to challenge the enforceability of any provision of this Agreement in any court of competent jurisdiction or arbitration, except as to validity under the Age Discrimination in Employment Act of 1967 that may arise after the date Executive executes this Agreement or any claims that cannot be waived under applicable law. Executive understands that nothing contained in this Agreement limits Executive’s ability to file a charge or complaint with the Equal Employment Opportunity Commission (“EEOC”), the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (“Government Agencies”). Executive further understands that this Agreement does not limit Executive’s ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. This Agreement does not limit Executive’s right to receive an award for information provided to any Government Agencies. Nothing in this Agreement shall prevent Executive’s participation in any legal proceedings against the Company or any Released Party in compliance with a summons that requires such participation, or Executive’s initiation of or participation in administrative proceedings or investigations of the EEOC or other Government Agencies; provided, however, that this Agreement shall prevent Executive from receiving any monetary or financial damages or recoveries from the Company or any Released Party or reinstatement with the Company in connection with any such proceedings or investigations which is not based on recovering or receiving an award paid by a Government Agency. Executive represents that Executive has not filed or asserted any claims whatsoever against the Company or any Released Party. Executive is not aware of any conduct by the Company or any Released Party that may violate any federal, state or local law, rule or regulation. Nothing contained in this Agreement shall prevent either Party from bringing any claim for breach or to otherwise take legal action to enforce its terms in accordance with the provisions hereof. Further, Executive does not release any claims for indemnification under the Indemnification Rights.

10.    Defend Trade Secrets Act Disclaimer; Other Statements.

a.Nothing in this Agreement is intended to discourage or restrict Executive from reporting any theft of trade secrets pursuant to the Defend Trade Secrets Act of 2016 (the “DTSA”) or other applicable state or federal law. The DTSA prohibits retaliation against an employee because of whistleblower activity in connection with the disclosure of trade secrets, so long as any such disclosure is made either (i) in confidence to an attorney or a federal, state, or local government official and solely to report or investigate a suspected violation of the law, or (ii) under seal in a complaint or other document filed in a lawsuit or other proceeding.

b.If Executive believes that any employee or any third party has misappropriated or improperly used or disclosed trade secrets or confidential information, Executive should report such activity to the Company’s Chairman of the Board. This Agreement is in addition to and not in lieu of any obligations to protect the Company’s trade secrets and confidential information which otherwise exists. Nothing in this Agreement shall limit, curtail or diminish the Company’s statutory rights under the DTSA, any applicable state law regarding trade secrets or common law.




c.Nothing contained in this Agreement or in the Continuing Obligations shall be deemed to prevent Executive from disclosing any information or facts concerning matters Executive reasonably believes to be illegal discrimination, illegal harassment; illegal retaliation; a wage and hour violation; or sexual assault or is recognized as against a clear public policy mandate. In addition, notwithstanding the continuing obligations in Section 9(h) of the Employment Agreement, nothing shall prohibit Executive from making truthful statements in connection with a legal proceeding or in response to a reference request, and nothing in Section 9(h) prohibits Executive from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that Executive has reason to believe is unlawful.

11.    Section 409A. The intent of the Parties is that the payments and benefits under this Agreement comply with or be exempt from Section 409A of the Code, and the regulations and guidance promulgated thereunder and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith.

12. Governing Law; Venue; Waiver of Jury Trial. This Agreement shall be subject to and governed by the laws of the State of Florida, without giving effect to the principles of conflicts of law under Florida law that would require or permit the application of the laws of a jurisdiction other than the State of Florida and irrespective of the fact that the Parties now or at any time may be residents of or engage in activities in a different state. Executive agrees that in the event of any dispute or claim arising under this Agreement and subject to Section 13 below, jurisdiction and venue shall be vested and proper, and Executive hereby consents to the jurisdiction of any court sitting in Palm Beach County, Florida, including the United States District Court for the Southern District of Florida. THE PARTIES HEREBY WAIVE A JURY TRIAL IN ANY LITIGATION ARISING UNDER OR RELATING TO THIS AGREEMENT.

13. Arbitration of Disputes. Unless otherwise prohibited by law or specified below, all disputes, claims and causes of action, in law or equity, arising from or relating to this Agreement or its enforcement, performance, breach, or interpretation shall be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. § 1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration held in Palm Beach County, Florida through Judicial Arbitration & Mediation Services/Endispute (“JAMS”) under the JAMS’ then applicable rules and procedures for employment disputes. The rules may be found online at www.jamsadr.com or upon written request to the Company. This paragraph is intended to be the exclusive method for resolving any and all claims by the Parties against each other relating to this Agreement and Executive’s employment; provided that Executive will retain the right to file administrative charges with or seek relief through any government agency of competent jurisdiction, and to participate in any government investigation, including but not limited to (a) claims for workers’ compensation, state disability insurance or unemployment insurance; (b) administrative claims brought before any state or federal governmental authority; provided, however, that any appeal from an award or from denial of an award of wages and/or waiting time penalties shall be arbitrated pursuant to the terms of this Agreement; and (c) claims for administrative relief from the United States Equal Employment Opportunity Commission and/or any similar agency in any applicable jurisdiction). Further, nothing in this paragraph is intended to prevent either Party from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration, including without limitation injunctive relief, in any court of competent jurisdiction pursuant to applicable law. Seeking any such relief shall not be deemed to be a waiver of such Party’s right to compel arbitration. Each Party in any such arbitration shall be responsible for its own attorneys’ fees, costs and necessary disbursement; provided, however, that if one Party refuses to arbitrate and the other Party seeks to compel arbitration by court order, if such other Party prevails, it shall be entitled to recover reasonable attorneys’ fees, costs and necessary disbursements.

14. Entire Agreement. This Agreement, together with Executive’s Indemnification Agreement, incorporates the entire understanding among the Parties with respect to the subject matter hereof. In reaching the agreements in this Agreement, neither Party has relied upon any representation or promise, oral or written, except those set forth herein. This Agreement has been duly authorized by the Parties, and duly executed on behalf of each Party by the duly authorized officers or principals and in the manner required by all laws and regulations applicable to each such entity.

15. Counterpart Signatures. This Agreement may be executed in one or more counterparts, and by the Parties in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute the same agreement. The Parties further agree that facsimile signatures or signatures scanned into .pdf (or similar) format and sent by e-mail shall be deemed original signatures.




16.    Assignment. This Agreement shall be binding upon and inure solely to the benefit of each Party identified herein, and nothing in this Agreement, express or implied, is intended to or shall confer upon any other person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. The Company may assign this Agreement to any successors (whether direct or indirect, by purchase, merger, consolidation or otherwise) to the business and/or assets of the Company. In as much as the duties of Executive hereunder are personal in nature, he may not assign this Agreement.

17. Severability. In the event any provision of this Agreement shall be held invalid or unenforceable, it shall be deemed modified, only to the extent necessary to make it lawful. To effect such modification, the said provision shall be deemed deleted, added to and/or rewritten, whichever shall most fully preserve the intentions of the Parties as originally expressed herein.

18. Voluntary Execution. Executive represents that Executive has read this Agreement in its entirety and has had the opportunity to consult with legal counsel prior to signing this Agreement and that Executive is fully aware of its contents and of its legal effect. Executive signs this Agreement of Executive’s own free will and act, without any legal reservations, duress, coercion or undue influence, and it is Executive’s intention that Executive be legally bound hereby. Executive is hereby advised he has the right to consult with an attorney of his own choosing before entering into this Agreement.

19. Period to Consider and Revoke. Executive acknowledges that Executive was offered the opportunity to consider this Agreement for a period of twenty-one (21) days from the time Executive received it on April 21, 2024, and is hereby advised to review it with an attorney of Executive’s choice. In the event Executive signs this Agreement and returns it to the Company in less than the 21-day period identified above, Executive hereby acknowledges that Executive has freely and voluntarily chosen to waive the time period allotted for considering this Agreement. EXECUTIVE AGREES THAT ANY MODIFICATIONS, MATERIAL OR OTHERWISE, MADE TO THIS AGREEMENT AFTER THE DATE EXECUTIVE RECEIVED IT DOES NOT RESTART OR AFFECT IN ANY MANNER THE ORIGINAL TWENTY-ONE (21) CALENDAR DAY CONSIDERATION PERIOD. This Agreement does not become effective until the eighth (8th) day after the date Executive signs this Agreement and provides the Company with an original thereof. Executive can revoke the Agreement at any time during the seven (7) days after signing it (the “Revocation Period”).

20.    Acceptance and/or Revocation. IMPORTANT NOTICE TO EXECUTIVE: Executive may accept this Agreement by signing it and returning it to the Company. Executive may exercise his right to revoke his decision to sign this Agreement by sending a written notice of revocation to the individual at the email address specified below by no later than the last day of the Revocation Period stated in Section 19 above:

Christine Chambers, Chief Financial Officer
cchambers@petmeds.com


If Executive exercises his right to revoke, his termination of employment shall be deemed to be a voluntary resignation, in which case he will only receive only his Accrued Compensation through the date of termination, the Unvested RSA Shares will be forfeited, and he will be entitled to no other benefits or compensation hereunder, under the Employment Agreement, or otherwise.


[signatures follow]










IN WITNESS WHEREOF, the Parties have duly executed this Transition and Separation Agreement as of the date first written above.

PETMED EXPRESS, INC.


By: /s/ Christine Chambers
Name: Christine Chambers
Title: Chief Financial Officer


EXECUTIVE:

/s/ Matt Hulett
Mathew Hulett, individually

Date of Signature: April 29, 2024

EX-10.2 3 pets-20240429xexx102.htm EX-10.2 Document


EXHIBIT 10.2
EXECUTIVE EMPLOYMENT AGREEMENT
THIS EXECUTIVE EMPLOYMENT AGREEMENT (hereinafter “Agreement”) is made and entered into effective as of April 29, 2024, by and between PETMED EXPRESS, INC., a Florida corporation (“Company”), and SANDRA CAMPOS, an individual residing in the State of New York (hereinafter called “Executive”).
RECITALS
WHEREAS, Company desires to retain the services of Executive as Chief Executive Officer and President of Company upon the terms and subject to the conditions set forth in this Agreement; and
WHEREAS, Executive desires to provide services to Company pursuant to the terms and conditions set forth in this Agreement
NOW THEREFORE, in consideration of the mutual covenants and promises set forth in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound, agree as follows:
1.DUTIES AND SCOPE OF EMPLOYMENT.
(a)Position and Duties. During the Term of Employment (as defined below), Executive shall be employed by Company as its Chief Executive Officer and President, reporting to the Board of Directors of Company (the “Board”). As Chief Executive Officer and President, Executive shall have such duties, powers, and responsibilities as are customarily assigned to a Chief Executive Officer and President of a publicly held corporation. In addition, Executive shall have such other duties and responsibilities as the Board may reasonably assign to her from time to time that are commensurate with and customary for a senior executive officer bearing Executive’s experience, qualifications, title, and position. Executive’s employment by Company shall be full-time, and Executive agrees to diligently and conscientiously devote all of her business time and attention to the performance of Executive’s duties hereunder and will not engage in any other business, profession, occupation, or activity for compensation; provided she may serve on the board of directors of one or more other companies or organizations with the specific prior written approval of the Board and only as long as serving on such boards does not prevent her from effectively and competently performing her duties under this Agreement. Nothing herein shall prohibit or restrict Executive from managing Executive’s own personal investments and/or engaging in civic, community, charitable, educational, religious, or non-profit activities as long as such activities do not materially interfere with Executive’s performance of her duties to Company as provided in this Agreement. As Chief Executive Officer and President, Executive will serve as Company’s “principal executive officer” for purposes of the rules and regulations of the Securities and Exchange Commission. Executive is a member of the Board, and Company shall, throughout the Term of Employment, nominate and recommend her election as member of the Board to the shareholders of Company.
(b)Location of Employment Services. Executive will spend no less than fifty percent (50%) of her business time working from Company’s principal executive offices or Company’s other business locations (including future business locations). Time expended traveling on Company business (excluding time spent commuting between Executive’s home and Company’s business locations) shall count toward the requirement set forth in the preceding sentence. The terms in this paragraph are subject to change by mutual written agreement between Executive and Company (acting under direction of the Board).
(c) Subsidiaries and Affiliates. With respect to Company’s direct and indirect subsidiaries, affiliated corporations, partnerships, or joint ventures (collectively, “Related Entities”), Executive shall perform the above-described duties to promote these Related Entities and to promote and protect their respective interests to the same extent as the interests of Company without additional compensation. This shall include serving, at the direction of the Board, as an officer or on the board of directors of Related Entities.
1




2.COMPENSATION.
(a)Base Salary. During the Term of Employment, Executive shall be paid a base salary of Five Hundred Fifty Thousand Dollars ($550,000.00) per year, pro-rated for any period less than twelve (12) months (the “Base Salary”).  The Base Salary will be paid in accordance with Company’s customary payroll procedures and will be subject to tax and other applicable withholdings.  The Base Salary may be increased by the Board (in its sole and absolute discretion), but not decreased, unless otherwise agreed to in writing by Executive or except in the case of a proportionate reduction in salary and wages of the senior management of Company.
(b)Signing Bonus. Executive will, on the first Company payroll date after the commencement of her employment with Company, receive a signing bonus of One Hundred Twenty Thousand Dollars ($120,000.00) (the “Signing Bonus”), which amount will be subject to tax and other applicable withholdings. In the event that Executive’s employment with Company terminates prior to the first (1st) anniversary of the commencement of her employment with Company (other than as a result of a Termination Upon Death, Termination for Disability, Termination Without Cause, or Good Reason Resignation, as those terms are defined below), then Executive shall repay the Signing Bonus to Company within fifteen (15) days after the effective date of termination of employment.
(c)Benefits. Executive is eligible to receive such medical, health, and other benefits as are provided by Company, in its discretion, from time to time to its employees generally. Executive will also be eligible to participate in Company’s 401(k) plan on the same basis as Company’s employees generally. Nothing in this Agreement will preclude Company from amending or terminating any of the employee benefit plans or programs applicable to employees of Company as long as such amendment or termination is applicable to all similarly-situated employees.
(d)Vacation. Executive will receive four (4) weeks of vacation each calendar year, with such period prorated for the period of time she is employed for partial calendar years.
(e)Bonuses. For the fiscal year of Company ending March 31, 2025 and each complete fiscal year of Company thereafter during the Term of Employment, Executive shall be eligible to receive an annual bonus (the "Annual Bonus"). Executive's annual target bonus opportunity shall be equal to One Hundred Percent (100%) of Base Salary at the annualized rate in effect on the last day of Company’s fiscal year for which the annual bonus is paid (the "Target Bonus") with an annual opportunity to receive a maximum bonus of Two Hundred Percent (200%) of Base Salary, each based on the achievement of performance goals determined by the Board and/or the Compensation Committee of the Board (the “Compensation Committee”); provided that, depending on results, Executive's actual bonus may be higher or lower than the Target Bonus, as determined by the Board based on the attainment of the performance goals. If threshold performance goals are not achieved, then Executive may not receive an Annual Bonus for such fiscal year. The Annual Bonus, if any, shall be paid by Company in cash in a reasonable period of time after the Board determines the achievement and amount of the Annual Bonus. Except as provided in Section 4(b)(iv)(C), to be eligible to receive the Annual Bonus, Executive must continue to be employed by Company on the date on which the Annual Bonus is paid.
(f)Equity Compensation.
(i)Initial Equity Grant. On the date on which Executive’s employment with Company commences, Executive will receive a grant (the “Initial Grant”) of restricted stock units (“RSUs”) under Company’s 2022 Employee Equity Compensation Plan (the “2022 Equity Plan”). The Initial Grant will consist of a number of RSUs equal to $2.0 million divided by the closing price of Company’s common stock on the Nasdaq Stock Market on the date of grant. The RSUs included in the Initial Grant will vest in one-third increments on each of the first three (3) anniversaries of the grant date of such RSUs and will otherwise be in accordance with the terms of Company’s standard form of RSU award agreement and the 2022 Equity Plan, as more particularly determined by the Board; and the terms of this Agreement.
2




(ii)Annual Equity Grants Awarded in 2024, 2025 and 2026. During the Term of Employment, on the date following each of Company’s 2024, 2025 and 2026 annual meetings of shareholders on which the Board determines to make annual equity grants in the normal course of Company’s compensation cycle (i.e., for each of the 2025, 2026 and 2027 fiscal years), Executive will receive a grant (each an “Annual Grant”) of RSUs and performance stock units (“PSUs”) under the 2022 Equity Plan or under any successor equity compensation plan as may be adopted by Company and approved by Company’s shareholders (the “Applicable Equity Plan”); provided, that making such grants at the times specified above will be contingent on Company having a sufficient number of shares available under the Applicable Equity Plan in order to make the grant; and provided further, Company will make reasonable efforts to have a sufficient number of shares available for timely grants, but if the grants are not made at the times specified above, they will be made when additional shares become available under the Applicable Equity Plan under the same terms as would have applied if the grants had not been delayed. Each Annual Grant will consist of a number of RSUs equal to $750,000 divided by the Reference Price (as defined below) and a number of PSUs equal to $750,000 divided by the Reference Price. For this purpose, “Reference Price” shall be an amount equal to the higher of (i) the closing price of Company’s common stock on the Nasdaq Stock Market on the date of grant, and (ii) $4.0 per share (with foregoing clause (ii) being subject to equitable adjustment by the Board for stock splits, stock dividends, reverse stock splits, and the like occurring after the date of this Agreement). Such RSUs will vest in one-third increments on each of the first three (3) anniversaries of the grant date of such RSUs and will otherwise be in accordance with the terms of Company’s standard form of RSU award agreement with respect to annual equity grants made in 2024, 2025 and 2026, respectively, and the Applicable Equity Plan and this Agreement, as more particularly determined by the Board. The PSUs will vest subject to achievement of performance goals to be determined by the Board and be earned over a three-year performance period, and such PSUs will otherwise be in accordance with the terms of Company’s standard form of PSU award agreement with respect to annual equity grants made in 2024, 2025 and 2026, respectively, and the Applicable Equity Plan and this Agreement, as more particularly determined by the Board. In the event that the Applicable Equity Plan authorizes Company to grant options to purchase shares of capital stock of Company, then upon the mutual written agreement of Company and Executive, Company may award options to Executive in lieu of all or a portion of the RSUs and PSUs contemplated by this section, provided the value of the stock options awarded shall have the same value as the RSUs and PSUs that would have otherwise been granted using such valuation method as Company and Executive may agree.
(iii)Future Annual Equity Grants. Executive will be eligible for such additional annual equity compensation grants in subsequent years as shall be determined by the Board in its sole discretion.
(g)Withholding. Company shall be entitled to deduct or withhold from any amounts owing from Company to Executive any federal, state, local or foreign withholding taxes, excise taxes or employment taxes imposed with respect to Executive’s compensation or other payments from Company, including wages, bonuses, distributions and/or the receipt or vesting of incentive equity.
(h)Reimbursement of Business Expenses. Executive shall be entitled to reimbursement for all reasonable and necessary out-of-pocket business, entertainment, and travel expenses incurred by Executive in connection with the performance of Executive's duties hereunder in accordance with Company's expense reimbursement policies and procedures and such other applicable policies and procedures as may be in effect from time to time, including without limitation any travel and expense policy and any code of conduct or code of ethics.
(i)Clawback Provisions. Notwithstanding any other provisions in this Agreement to the contrary, any bonus (if any) and other compensation paid to Executive will be subject to such potential clawback as may be required to be made pursuant to applicable federal or state law, or pursuant to applicable stock exchange listing requirements, governing potential clawback of executive compensation upon a determination by legal counsel to Company that clawback is required by federal or state law or applicable stock exchange listing requirements. Specifically, Executive agrees that she will be subject to, and shall comply with, the PetMed Express, Inc. Executive Compensation Recovery Policy.
3




3.TERM OF EMPLOYMENT. The term of Executive’s employment under this Agreement shall commence on the date of this Agreement (the “Effective Date”) and shall continue until, and including, the last day of the 36-month period commencing on the Effective Date, unless terminated earlier in accordance with Section 4 of this Agreement (the “Term of Employment”). The Term of Employment shall automatically extend, as of each date it would otherwise expire, for a period of one (1) additional year, unless (i) either party gives notice of nonrenewal at least sixty (60) days before the Term of Employment is next scheduled to expire (a “Nonrenewal Notice”) or (ii) this Agreement is earlier terminated in accordance with Section 4 below.
4.TERMINATION.
(a)Types of Terminations. This Agreement and Executive’s employment hereunder shall terminate upon the happening of any of the following events:
(i)Executive’s death (“Termination Upon Death”);
(ii)the effective date of a written notice sent to Executive stating Company’s determination, made in good faith, that due to a mental or physical condition, Executive has been unable and failed to substantially render the services to be provided by Executive to Company for a period of at least (x) 180 days out of any consecutive 360 days or (y) 90 consecutive days (“Termination For Disability”);
(iii)the effective date of a written notice sent to Executive stating Company’s determination that it is terminating Executive’s employment for Cause (as defined below) (“Termination For Cause”);
(iv)the effective date of a termination set forth in a notice sent to Executive stating that Company is terminating Executive’s employment without Cause or for no stated reason (“Termination Without Cause”), which notice must be given by Company to Executive at least thirty (30) days in advance of the intended date of termination;
(v)the effective date of a termination based on a notice sent to Company from Executive stating that Executive is resigning without Good Reason or for no stated reason, which notice must be given by Executive to Company at least sixty (60) days in advance of the intended date of termination (a “Voluntary Resignation”); or,
(vi)a Good Reason Resignation (as defined below) by Executive, provided that such Good Reason Resignation is effected in accordance with the procedures set forth in Section 4(c)(v) below.
As used herein, the term “Cause” shall mean (i) commission of a willful act of dishonesty in the course of Executive’s duties hereunder or misappropriation of funds, theft, or embezzlement by Executive of funds or property of Company or any Related Entity, (ii) conviction by a court of competent jurisdiction of, or plea of no contest to, a crime constituting a felony or conviction in respect of, or plea of no contest to, any act involving fraud, dishonesty or moral turpitude, (iii) Executive's engagement in dishonesty, illegal or disloyal conduct, or willful or grossly negligent misconduct, which is, in any such case, injurious to the interests, reputation or business of Company or its Related Entities as determined by the Board, (iv) Executive’s performance under the influence of controlled substances (other than those taken pursuant to a medical doctor’s orders), or continued habitual intoxication, during working hours, (v) frequent or extended, and unjustifiable, absenteeism, (vi) Executive’s personal misconduct or refusal or material failure to timely perform her duties and responsibilities or to timely carry out the lawful directives of Company or any Related Entity, which, if capable of being cured shall not have been cured, within 30 days after Company shall have advised Executive in writing of its intention to terminate Executive’s employment; provided, that such right to cure shall not apply to any subsequent act or omission of a substantially similar nature or type, or (vii) Executive’s material non-compliance with the terms of this Agreement or any policy of Company or any Related Entity, which, if capable of being cured, shall not have been cured within 30 days after Company shall have advised Executive in writing of its intention to terminate Executive’s employment for such reason.
(b)Effect of Termination.
4




(i)In the event of Termination Upon Death or Termination For Disability, Executive (or Executive’s legal representative) shall be entitled to receive (i) on the next payroll date, wages in an amount equal to any earned but unpaid Base Salary owing by Company to Executive as of the termination date; (ii) within fourteen (14) days after Executive’s termination date, the value (based on Executive’s rate of annualized Base Salary on the termination date (but disregarding any decreases in Base Salary that are not permitted under Section 2(a) or that could serve as a trigger for a Good Reason Resignation) of her accrued but unused vacation days; and (iii) within the normal course, reimbursement for her business expenses incurred before the termination date as determined under Section 2(h) (collectively, the “Accrued Payments”).
(ii)In the event of a Termination For Cause or a Voluntary Resignation (or any other termination or resignation by Executive other than a Good Reason Resignation), Executive shall be entitled to receive only an amount equal to any Accrued Payments.
(iii)In the event of Termination Without Cause, a termination by Company pursuant to a Nonrenewal Notice delivered by Company, or a Good Reason Resignation, any of which occurs during a period that is outside the twelve (12)-month period commencing upon the date of a Change of Control, then upon Executive’s separation from service (within the meaning given to such term in Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”):
(A)Executive shall be entitled to receive the Accrued Payments; and
(B)Executive shall be entitled to separation compensation (“Separation Compensation”) in the form of wages in an amount equal to twelve (12) months of Executive’s Base Salary (at the rate in effect at time of termination but disregarding any decreases in Base Salary that are not permitted under Section 2(a) or that could serve as a trigger for a Good Reason Resignation), which amount shall be payable in the manner set forth below; and
(C)For each separate award of RSUs held by Executive as of the termination date, a number of Executive’s unvested RSUs included in such award will vest equal to (i) the aggregate number of RSUs included in such award multiplied by a fraction, the numerator of which is the number of days during the entire vesting period of such award during which Executive was employed by Company and the denominator of which is the total number of days in the entire vesting period of such award, minus (ii) the aggregate number of RSUs included in such award that vested prior to the effective date of termination. Any RSUs that vest pursuant to the terms of this subsection will be paid to Executive no later than the 15th day of the third month following the end of Company’s fiscal year in which such vesting occurs; and
(D)Company shall pay to Executive, in equal monthly installments (and subject to applicable tax and other withholdings), an amount equal to the premium payments for continuing medical, dental and vision coverage for Executive (and Executive’s family, if covered under Company’s group health plan as of the effective date of termination of employment) under the Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA) for the twelve (12)-month period following the effective date of termination, but only to the extent Executive and Executive’s family elects and remains entitled to COBRA continuation coverage during such time period (“Benefit Payments”).
(iv)In the event of Termination Without Cause, a termination by Company pursuant to a Nonrenewal Notice delivered by Company, or a Good Reason Resignation, any of which occurs during the twelve (12)-month period commencing upon the date of a Change of Control, then upon Executive’s separation from service (within the meaning given to such term in Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”):
(A)Executive shall be entitled to receive the Accrued Payments; and
5




(B)Executive shall be entitled to receive Separation Compensation consisting of wages in an amount equal to twenty-four (24) months of Executive’s Base Salary (at the rate in effect at time of termination but disregarding any decreases in Base Salary that are not permitted under Section 2(a) or that could serve as a trigger for a Good Reason Resignation), which amount shall be payable in the manner set forth below; and
(C)Executive shall be entitled to a cash payment equal to the product of (i) the dollar amount of Executive’s Target Bonus for Company’s fiscal year in which Executive’s termination date occurs, and (ii) a fraction, the numerator of which is the number of days during such fiscal year through and including Executive’s termination date, and the denominator of which is 365 (a “Pro Rata Bonus Payment”). Any amount payable under this section will be paid in a lump sum to Executive at the same time the annual bonus is paid to Company’s employees who remained actively employed for the full year in which Executive’s termination date occurs; and
(D)All of Executive’s unvested RSUs will vest as of Executive’s termination date and will be paid to Executive no later than the 15th day of the third month following the end of Company’s fiscal year in which such vesting occurs; and
(E)Executive’s unvested PSUs will vest as of Executive’s termination date with all performance criteria based on Company’s or Executive’s performance deemed satisfied at target (or in the case of PSUs based on relative total shareholder return, deemed satisfied based on the actual percentile achievement against the applicable index measured as of shortened performance period ending on the earlier of Executive’s termination date or the date on which Company’s common stock ceases to trade publicly). Such vested PSUs will be paid to Executive no later than the 15th day of the third month following the end of Company’s fiscal year in which such vesting occurs; and
(F)Company shall provide to Executive, in equal monthly installments (and subject to applicable tax and other withholdings), an amount equal to the premium payments for continuing medical, dental and vision coverage for Executive (and Executive’s family, if covered under Company’s group health plan as of the effective date of termination of employment) under the Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA) for the eighteen (18)-month period following the effective date of termination, but only to the extent Executive and Executive’s family elects and remains entitled to COBRA continuation coverage during such time period (also referred to as “Benefit Payments”).
(c)Additional Provisions.
(i)Subject to the provisions in the following paragraph, any amounts to be paid pursuant to Section 4(b)(iii)(B) or Section 4(b)(iv)(B) shall be paid in accordance with Company’s existing payroll or bonus payment practices, as applicable, subject to applicable taxes and withholdings.
(ii)The Separation Compensation described in Section 4(b)(iii)(B) or Section 4(b)(iv)(B) (if payable) will be paid according to Company’s normal payroll cycle in installments (“Separation Payments”). The Separation Payments will be paid over the twelve (12)-month period or twenty-four (24)-month period, as applicable, beginning with the first payroll after Executive’s separation from service; provided, the first payment will be delayed until the first payroll that occurs at least seven (7) days after Company’s receipt of a fully executed Release (as defined below) with the first payment inclusive of all Separation Payment amounts that would have been payable through the date of such first payment. Separation Payments and Benefit Payments, as well as any Pro Rata Bonus Payment, shall be subject to tax withholdings and other required withholdings. Notwithstanding the foregoing, Executive’s right to receive any Separation Payments and Benefit Payments pursuant to this Agreement is conditioned upon Executive signing (and not revoking), by the twenty-first (21st) day after the date Executive receives a copy of a general release of claims (except those rights arising under this Agreement) in a form provided by Company (the “Release”). In the event that any payment described in Section 4(b)(iii) or Section 4(b)(iv) (as applicable) is not exempt from Code Section 409A, the payment timing is based on the signing of this Release, and the period in which Executive could timely sign and return the release spans two (2) calendar years, such payment will in all events be made in the second such calendar year.
6




(iii)Notwithstanding any provision of this Agreement to the contrary, the obligations and commitments under Section 5 of this Agreement shall survive and continue in full force and effect in accordance with their terms notwithstanding any termination of Executive’s employment for any reason or termination of this Agreement for any reason.
(iv)Notwithstanding anything in this Agreement to the contrary, Company shall have no obligation to pay any amounts payable under Section 4(b)(iii)(B) through (D) or 4(b)(iv)(B) through (F) of this Agreement (as applicable) during such times as Executive is in breach of Section 5 or Section 14 of this Agreement, after Company provides Executive with notice of such breach.
(v)Executive shall have the right to resign her employment for Good Reason (a “Good Reason Resignation”) if she has provided written notice to Company of the existence of the circumstances constituting Good Reason within thirty (30) days of the initial existence of such grounds and Company has had at least thirty (30) days from the date on which such notice is provided to cure such circumstances (and has failed to cure such circumstances within such period). If Company has not, within such thirty (30)-day period, cured the circumstances providing grounds for termination for Good Reason, Executive must terminate her employment within thirty (30) days thereafter. If Executive does not terminate her employment for Good Reason within such thirty (30)-day period after the expiration of Company’s cure period in the preceding sentence, Executive will be deemed to have waived her right to terminate for Good Reason with respect to such grounds. “Good Reason” shall be defined as follows:
(A)If Executive’s resignation occurs at any time other than the twelve (12)-month period commencing on the date of a Change of Control, “Good Reason” means the occurrence of any one or more of the following events to the extent that there is, or would be if not corrected, a material negative change in Executive’s employment relationship with Company: (A) there is a material adverse change or material diminution in Executive’s duties, responsibilities, functions or title with Company, (B) there is a material reduction in the compensation or equity grants payable to Executive hereunder, or (C) there is a material breach by Company of the provisions of this Agreement.
(B)If Executive’s resignation occurs during the twelve (12)-month period commencing on the date of a Change of Control, “Good Reason” means the occurrence of any one or more of the following events to the extent that there is, or would be if not corrected, a material negative change in Executive’s employment relationship with Company: (A) there is a material adverse change or material diminution in Executive’s duties, responsibilities, functions or title with Company, (B) there is a material reduction in the compensation or equity grants payable to Executive hereunder, (C) there is a material breach by Company of the provisions of this Agreement, (D) if Company is no longer a publicly traded company as a result of the Change of Control, Executive ceases to directly report to the board of directors of Company’s ultimate parent company, or (E) the failure of any successor to Company to expressly assume and agree to discharge Company’s obligations to Executive under this Agreement in substantially the same form and substance as Company.
(vi)For purposes hereof, the term “Change of Control” shall have the meaning set forth in the 2022 Equity Plan, provided that in the event that Company adopts a new or amended employee equity plan, then the term “Change of Control” shall have the meaning set forth in such new or amended employee equity plan.
(vii)Upon termination of Executive’s employment for any reason, Executive shall be deemed to have resigned from all positions and directorships held with Company and its Related Entities, including, without limitation, any position as an officer, agent, trustee, or consultant of Company or any Related Entity, unless the Board expressly determines otherwise. Upon request of Company, Executive shall promptly sign and deliver to Company any and all documents reflecting such resignations as of the effective date of termination.
7




5.NON-COMPETITION, NON-SOLICITATION AND CONFIDENTIALITY.
(a)Certain Definitions.
“Company’s Business” means the online sale, marketing, or distribution of (i) prescription and non-prescription pet medications or health products or services, or (ii) foods, beverages, or supplies for dogs, cats, and horses.
“Competitor” means any company, other entity, or association or individual that directly or indirectly engages in Company’s Business.
“Confidential Information” means any information with respect to Company or any Related Entity or Company’s Business, including, but not limited to: the trade secrets of Company and any Related Entities; manuals and documentation; databases; Company’s and any Related Entity’s existing and prospective clients and customers, sales lists, supplier and vendor lists, marketing plans, business plans, industry information acquired or prepared by Company, product specifications, product ideas, price lists, and other similar and related information in whatever form. The term “Confidential Information” does not include, and there shall be no obligation hereunder with respect to, information that is generally available or becomes generally available to the public other than as a result of a disclosure by Executive not otherwise permissible hereunder.
(b)Non-competition. Executive covenants and agrees that during the period of her employment with Company and during the Restricted Period (as defined below), Executive will not engage in or participate in Company’s Business or own, manage, engage in, participate in (on behalf of herself or any other person or entity), operate, control, become employed by, or render any service to (whether as owner, beneficial owner, partner, associate, agent, independent contractor, consultant, lender, employee, stockholder, director or officer or in any other capacity), or invest in any Competitor anywhere in the United States of America or Canada or any other place outside of the United States of America in which Company markets, sells, or distributes products. Notwithstanding the foregoing, nothing in this paragraph shall prohibit Executive from owning 2% or less of the stock of any public traded company. The term “Restricted Period” means the twelve (12)-month period immediately following the termination of Executive’s employment with Company, regardless of the reason for termination and regardless of who effects the termination. Notwithstanding the foregoing, nothing in this paragraph will prohibit Executive from being employed by or rendering services to a business enterprise with multiple separately managed business units (one or more of which engages in Company’s Business) so long as (i) Executive does not work in or provide services to the business unit that engages in Company’s Business, (ii) the business unit that engages in Company’s Business is not the principal business unit of the business enterprise; and (iii) Executive otherwise complies with the terms of this Agreement and does not engage in activities that actually or potentially competes with Company’s Business.
(c)Non-solicitation. Executive covenants and agrees that, during the Restricted Period, she will not on Executive’s own behalf or on behalf of any other person or entity, (A) hire, cause to be hired, or solicit or attempt to solicit the employment of any person who was employed by Company or any Related Entity at any time during the one (1)-year period immediately preceding the Restricted Period, or seek to persuade any employee of Company to discontinue employment, (B) solicit or encourage any customer, client or supplier of Company or any independent contractor providing services to Company to terminate or diminish its relationship with Company, (C) seek to persuade any customer, client or supplier, or prospective customer, client or supplier, of Company to conduct with anyone else any business or activity that such customer, client or supplier, or prospective customer, client or supplier, conducts or could conduct with Company or any Related Entity, or (D) solicit or encourage any person or entity that has or does refer business to Company for the purpose of having such person or entity refer business to a competing business.
8




(d)Representations and Covenants by Executive. Executive represents and warrants that: (i) Executive’s execution, delivery and performance of this Agreement do not and will not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order, judgment or decree to which Executive is a party or by which Executive is bound; (ii) Executive is not a party to or bound by any employment agreement, noncompete agreement or confidentiality agreement with any other person or entity (other than Company) and Executive is not subject to any other agreement that would prevent or in any manner restrict Executive from performing Executive’s duties for Company or otherwise complying with this Agreement; (iii) Executive is not subject to or in breach of any nondisclosure agreement, including any agreement concerning trade secrets or confidential information owned by any other party; and (iv) upon the execution and delivery of this Agreement by Company, this Agreement shall be the valid and binding obligation of Executive, enforceable in accordance with its terms.
(e)Non-disclosure of Confidential Information. Executive hereby acknowledges and represents that Executive has consulted with independent legal counsel regarding Executive’s rights and obligations under this Agreement and that Executive fully understands the terms and conditions contained herein and Executive agrees that Executive will not, directly or indirectly: (i) use, disclose, reverse engineer or otherwise exploit for Executive’s own benefit or for the benefit of anyone other than Company the Confidential Information except as authorized by Company; (ii) during Executive’s employment with Company, use, disclose, or reverse engineer (x) any confidential information or trade secrets of any former employer or third party, or (y) any works of authorship developed in whole or in part by Executive during any former employment or for any other party, unless authorized in writing by the former employer or third party; or (iii) upon Executive’s resignation or termination (x) retain Confidential Information, including any copies existing in any form (including electronic form), that are in Executive’s possession or control, or (y) destroy, delete or alter the Confidential Information without Company’s consent. Notwithstanding the foregoing, Executive may use the Confidential Information in the course of performing Executive’s duties on behalf of Company or any Related Entity provided that such use is made in good faith and on a reasonable basis. Notwithstanding the terms of this Agreement, Confidential Information may be disclosed by Executive when and to the limited extent compelled by written notice from a government agency or when and to the limited extent compelled by legal process or court order by a court of competent jurisdiction, provided that, to the extent legally permissible, Executive shall give Company prompt written notice of such request or order and the Confidential Information to be disclosed as far in advance of its disclosure as possible so that Company may seek an appropriate protective order. Upon separation of employment or suspension (for any reason), Executive will immediately surrender possession of all Confidential Information to Company. Nothing in this Agreement is intended to discourage or restrict Executive from reporting any theft of trade secrets pursuant to the Defend Trade Secrets Act of 2016 (the “DTSA”) or other applicable state or federal law. The DTSA prohibits retaliation against an employee because of whistleblower activity in connection with the disclosure of trade secrets, so long as any such disclosure is made either (i) in confidence to an attorney or a federal, state, or local government official and solely to report or investigate a suspected violation of the law, or (ii) under seal in a complaint or other document filed in a lawsuit or other proceeding. In addition, nothing contained in this Agreement shall be deemed to prevent Executive from disclosing any information or facts concerning matters Executive reasonably believes to be illegal discrimination, illegal harassment; illegal retaliation; a wage and hour violation; sexual assault; or acts recognized as against a clear public policy mandate.
(f)Inventions and Patents. Executive acknowledges that all (i) inventions, innovations, improvements, developments, methods, designs, analysis, drawings, reports, processes, novel concepts, ideas, copyrights, trademarks and service marks relating to any present or prospective activities of Company, including but not limited to marketing plans or techniques, processes, software, formula, techniques and improvements to the foregoing or to know how, and all similar or related information (whether or not patentable) that relate to Company’s Business, (ii) research and development and (iii) existing or future products or services that are, to any extent, conceived, developed or made by Executive while employed by Company or any Related Entity (“Work Product”) belong to Company or such Related Entity. Executive shall promptly disclose such Work Product to Company and, at the cost and expense of Company, perform all actions reasonably necessary or requested by Company (whether during or after the Term of Employment) to establish and confirm such ownership (including, without limitation, executing assignments, consents, powers of attorney and other instruments).
9




(g)Additional Acknowledgements.
(i)Executive acknowledges that (x) Executive’s position is a position of trust and responsibility with access to Confidential Information of Company, (y) the Confidential Information, and the relationship between Company and each of its employees, customers, tenants, and vendors, are valuable assets of Company and may not be converted to Executive’s own use and (z) the restrictions contained in this Section 5 are reasonable and necessary to protect the legitimate business interests of Company and will not impair or infringe upon Executive’s right to work or earn a living after Executive’s employment with Company ends.
(ii)Executive acknowledges that monetary damages will not be an adequate remedy for Company in the event of a breach of this Agreement and that it would be impossible for Company to measure damages in the event of such a breach. Therefore, Executive agrees that, in addition to other rights that Company may have at law or equity, Company is entitled to seek an injunction preventing Executive from any breach of this Agreement.
(iii)In the event of a breach or violation of any restriction in Section 5(b) or 5(c) of this Agreement, the time limitations set forth in such restriction shall be extended for a period of time equal to the period of time until such breach or violation has been cured.
(iv)The parties agree that the foregoing restrictive covenants are reasonable and necessary to protect Company’s legitimate business interests. The parties, however, do not intend to include a provision that contravenes the public policy of any state. Therefore, if any provision of this Section 5 is unlawful, against public policy or otherwise declared void, such provision shall not be deemed part of this Agreement, which otherwise shall remain in full force and effect. If, at the time of enforcement of this Agreement, a court or other tribunal holds that the duration, scope or area restriction stated herein is unreasonable under the circumstances then existing, the parties agree that the court should enforce the restrictions to the extent it deems reasonable.
(v)Executive hereby agrees that prior to accepting employment with any other person or entity during the term of employment or during the Restricted Period following the termination date, Executive will provide such prospective employer with written notice of the existence of this Agreement and the provisions of this Section 5 of this Agreement, with a copy of such notice delivered simultaneously to Company in accordance with Section 8 of this Agreement.
(vi)Notwithstanding any provision of this Agreement, the obligations and commitments of this Section 5 shall survive and continue in full force and effect in accordance with their terms notwithstanding any termination of Executive’s employment for any reason or termination of this Agreement for any reason.
6.REMEDIES. Executive agrees and acknowledges that a breach on the part of Executive of the covenants contained in Section 5 may cause irreparable harm to Company and that damages arising out of such breach may be difficult to determine.  Executive, therefore, further agrees that in addition to all other remedies provided at law or at equity, Company shall be entitled to seek specific performance and temporary and permanent injunctive relief, from any court of competent jurisdiction restraining any further breach of any such covenant by Executive, her employers, employees, partners, agents or other associates, or any of them, without the necessity of proving actual damage to Company by reason of any such breach.
7.ASSIGNMENT. Company may assign this Agreement and any of the rights or obligations hereunder to any third party in connection with the sale, merger, consolidation, reorganization, liquidation or transfer, in whole or in part, of Company’s control and/or ownership of its assets or business.  In such event, Executive continues to be bound by the terms of this Agreement.  An assignment of this Agreement by Executive or any right or obligation hereunder is strictly prohibited.
10




8.NOTICES. All notices and other communications provided to either party hereto under this Agreement shall be in writing and delivered by certified or registered mail, postage prepaid, by e-mail if also sent via first class U.S. mail, or by national overnight delivery service (such as Federal Express), to such party at its/her address set forth below, or at such other address as may be designated by either party in conformity with the provisions of this Section 8, with any such notices being deemed given when actually received by the recipient.:
If to Company:    c/o PetMed Express, Inc.
420 South Congress Avenue
Delray Beach, FL 33445
    E-mail: cchambers@petmeds.com
If to Executive:    To Executive’s address as reflected on the payroll records of Company
9.GOVERNING LAW. This Agreement shall be subject to and governed by the laws of the State of Florida, without giving effect to the principles of conflicts of law under Florida law that would require or permit the application of the laws of a jurisdiction other than the State of Florida and irrespective of the fact that the parties now or at any time may be residents of or engage in activities in a different state.
10.DISPUTE RESOLUTION.
(a)Arbitration. Company and Executive agree that any dispute, controversy or claim arising out of or related in any way to Executive’s employment relationship with Company, the termination of that relationship, this Agreement, and/or any breach of this Agreement, shall be submitted to and decided by binding arbitration in Palm Beach County in the State of Florida. By accepting employment with Company, Executive accepts and consents to be bound by this agreement to arbitrate (the “Arbitration Provision”). This Arbitration Provision covers all grievances, disputes, claims or causes of action that otherwise could be brought in a federal, state or local court under applicable federal, state or local laws, arising out of or relating to Executive’s employment with Company and the termination thereof, including claims Executive may have against Company or against its officers, directors, supervisors, managers, employees or agents in their capacity as such or otherwise. The claims covered by this Arbitration Provision include, but are not limited to, claims for breach of any contract or covenant (express or implied); tort claims; claims for wages or other compensation due; claims for wrongful termination (constructive or actual); claims for discrimination or harassment (including, but not limited to, harassment or discrimination based on race, age, color, sex, gender, national origin, alienage or citizenship status, creed, religion, marital status, partnership status, military status, predisposing genetic characteristics, medical condition, psychological condition, mental condition, criminal accusations and convictions, disability, sexual orientation, or any other trait or characteristic protected by federal, state or local law); claims for violation of any federal, state, local or other governmental law, statute, regulation or ordinance; and claims or disputes concerning the validity, enforceability, arbitrability or scope of this Arbitration Provision. Claims not covered by this Arbitration Provision are claims for workers’ compensation or unemployment compensation benefits; at Company’s sole option, claims by Company for injunctive or other equitable relief for the breach or threatened breach of the covenants above; and any other claims that, as a matter of law, Company and Executive cannot agree to arbitrate. Nothing herein shall impair Executive’s right to report possible violations of law to any government agency or cooperate with any agency’s investigation.
Company and Executive expressly intend and agree that: (a) class, collective and/or representative action procedures shall not be asserted, nor will they apply, in any arbitration pursuant to this Arbitration Provision; (b) Executive will not assert class, collective and/or representative action claims against Company or its officers, directors, supervisors, managers, employees or agents in arbitration or otherwise; and (c) Executive shall only submit her own, individual claims in arbitration and will not seek to represent the interests of any other person. Further, Company and Executive expressly intend and agree that any claims by Executive will not be joined, consolidated or heard together with claims of any other employee.
The Arbitrator shall apply the substantive law of the State of Florida or federal law (and the law of remedies, if applicable) as applicable to the claims asserted and shall apply the same rules of evidence as a federal court. Arbitration shall be administered in accordance with the AAA Employment Arbitration Rules in effect at the time the arbitration is commenced.
11




To the extent not provided for in the AAA Employment Arbitration Rules, the Arbitrator has the power to order discovery upon a showing that discovery is necessary for a party to have a fair opportunity to present a claim or defense, and the Arbitrator shall decide all discovery disputes. Executive’s agreements to arbitrate and participate only in her individual capacity are contracts under the Federal Arbitration Act and any other laws validating such agreements. No failure to strictly enforce these agreements will constitute a waiver or create any future waivers. If any part of this Arbitration Provision is adjudged to be void or otherwise unenforceable, in whole or in part, the void or unenforceable portion shall be severed and such adjudication shall not affect the validity of the remainder of this Arbitration Provision and/or this Agreement. Any arbitral award determination shall be final and binding upon the parties. Judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof.
Notwithstanding the foregoing, any claims or actions, whether for damages, injunctive relief or other relief, for any violation or breach of the covenants set forth in Section 5 and the remedies set forth in Section 6, including but not limited to the actions described in Section 6, (i) shall be excluded from the Arbitration Provision and its applicability, and (ii) shall be resolved exclusively in the State of Florida in the state courts located in Palm Beach County, Florida or in the United States District Court for the Southern District of Florida.
(b)Injunctive Relief. Nothing in the Arbitration Provision and/or this Agreement shall prevent Company from applying to and obtaining from a court of competent jurisdiction a writ of attachment, a temporary restraining order, a permanent restraining order, a temporary injunction, a permanent injunction, or other injunctive relief available to safeguard and protect Company’s interests, including but not limited to Company’s interests in the restrictive covenants contained herein. Any action, suit or other proceeding initiated for these purposes shall be brought in the State of Florida in the state courts located in Palm Beach County, Florida or in the United States District Court for the Southern District of Florida and Executive agrees to submit herself to the exclusive personal jurisdiction and venue of those courts for such purposes.
(c)WAIVER OF JURY TRIAL. COMPANY AND EXECUTIVE UNDERSTAND AND AGREE THAT THEY ARE WAIVING ANY RIGHT TO JURY TRIAL WITH RESPECT TO ANY DISPUTE, CONTROVERSY OR CLAIM ARISING OUT OF OR RELATED IN ANY WAY TO EXECUTIVE’S EMPLOYMENT RELATIONSHIP WITH COMPANY, THE TERMINATION OF THAT RELATIONSHIP, THIS AGREEMENT, AND/OR ANY BREACH OF THIS AGREEMENT. COMPANY AND EXECUTIVE EXPRESSLY ACKNOWLEDGE AND AGREE THAT THEY ARE WAIVING ANY RIGHT THEY MAY HAVE TO A JURY TRIAL BY SIGNING THIS AGREEMENT.
11.INVALIDITY. Any provision herein which in any way contravenes the applicable laws of any country, state or jurisdiction shall be severed from this Agreement and deemed not to be considered part of this Agreement and this Agreement shall not be invalid as a whole because of any such determination.
12.INDULGENCE. No indulgence extended by either party hereto to the other party shall be construed as a waiver of any breach on the part of such other party, nor shall any waiver of one breach be construed as a waiver of any rights or remedies with respect to any subsequent breach.
13.ENTIRE AGREEMENT AND CHANGES TO BE IN WRITING. Except as otherwise indicated herein, this Agreement shall constitute the entire agreement between Executive and Company concerning the subject matter hereof. This Agreement supersedes and preempts any prior employment agreement or other understandings, agreements or representations by or among the parties, written or oral, that may have related to the subject matter hereof. No provisions of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing, signed by Executive and an authorized officer of Company.
14.NON-DISPARAGEMENT. Executive agrees to not make any statements, written or oral, while employed by Company and thereafter, which would be reasonably likely to disparage or damage Company and its Related Entities or the personal or professional reputation of any present or former employees, officers or members of the managing or directorial boards or committees of Company or the Related Entities. This Section 14 shall not prohibit Executive from making truthful statements in connection with a legal proceeding or in response to a reference request, and nothing in this Section 14 prohibits Executive from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that Executive has reason to believe is unlawful.
12




15.STRICT COMPLIANCE. Executive’s or Company’s failure to insist upon strict compliance with any provision of this Agreement or the failure to assert any right Executive or Company may have hereunder shall not be deemed to be a waiver of such provision or right or any other provision or right of this Agreement. The waiver, whether express or implied, by either party of a violation of any of the provisions of this Agreement shall not operate or be construed as a waiver of any subsequent violation of any such provision.
16.280G. Notwithstanding any other provision of this Agreement, or any other agreement, plan, or arrangement to the contrary, if any portion of any payment or benefit to Executive under this Agreement, or under any other agreement, plan, or arrangement (in the aggregate, “Total Payments”), would constitute an “excess parachute payment” under Section 280G of the Code, and would, but for this Section 16, result in the imposition on Executive of an excise tax (the “Excise Tax”) under Section 4999 of the Internal Revenue Code (the “Code”), then the Total Payments to be made to Executive shall either be (a) delivered in full, or (b) delivered in a reduced amount that is $1.00 less than the amount that would cause any portion of such Total Payments to be subject to the Excise Tax, whichever of the foregoing results in the receipt by Executive of the greatest benefit on an after-tax basis (taking into account the Excise Tax, as well as the applicable federal, state, and local income and employment taxes, for which Executive shall be deemed to pay at the highest marginal rate for the applicable calendar year). To the extent the foregoing reduction applies, then any such payment or benefit shall be reduced or eliminated by applying the following principles, in order: (1) the cash payments that are exempt from Section 409A shall first be reduced (if necessary, to zero); (ii) then, if further reductions are necessary, the cash payments that are not exempt from Section 409A shall be reduced (if necessary, to zero); and (iii) then, if further reductions are necessary, the other benefits that are exempt from Section 409A shall be reduced (if necessary, to zero); and (iv) finally, if still further reductions are necessary, the other benefits that are not exempt from Section 409A shall be forfeited. The determination of whether the Excise Tax or the foregoing reduction will apply will be made by independent auditors selected and paid by Company (which may be the regular auditor of Company, acting with the advice of Company’s outside legal counsel).
17.COMPLIANCE WITH SECTION 409A.
(a)General Compliance. This Agreement is intended to comply with Section 409A of the Code (“Section 409A”) or an exemption thereunder and shall be construed and administered in accordance with Section 409A. Any payments under this Agreement that may be excluded from Section 409A either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent possible. For purposes of Section 409A, each installment payment provided under this Agreement shall be treated as a separate payment. Any payments to be made under this Agreement upon a termination of employment shall only be made upon a "separation from service" under Section 409A. Notwithstanding the foregoing, Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A, and in no event shall Company be liable for all or any portion of any taxes, penalties, interest, or other expenses that may be incurred by Executive on account of non-compliance with Section 409A. To the extent that any payments made or benefits provided pursuant to this Agreement are reimbursements or in-kind payments, to the extent necessary to comply with Code Section 409A, the amount of such payments or benefits during any calendar year will not affect the amounts or benefits provided in any other calendar year, the payment date will in no event be later than the last day of the calendar year immediately following the calendar year in which an expense was incurred, and the right to any such payments or benefits will not be subject to liquidation or exchange for another payment or benefit.
(b) Specified Employee. Notwithstanding any other provision of this Agreement, if any payment or benefit provided to Executive in connection with Executive’s termination of employment is determined to constitute "nonqualified deferred compensation" within the meaning of Section 409A and Executive is determined to be a "specified employee" as defined in Section 409A(a)(2)(b)(i), then such payment or benefit shall not be paid until the first payroll date to occur following the six-month anniversary of the date of termination of employment or, if earlier, on Executive's death (the "Specified Employee Payment Date"). The aggregate of any payments that would otherwise have been paid before the Specified Employee Payment Date shall be paid to Executive in a lump sum on the Specified Employee Payment Date and thereafter, any remaining payments shall be paid without delay in accordance with their original schedule.
13




18.SURVIVAL. Any provision of this Agreement that is expressly or by implication intended to survive the termination of this Agreement shall survive or remain in effect after the termination of this Agreement.
19.COUNTERPARTS. This Agreement may be executed in separate counterparts, either one of which need not contain the signature of more than one party, but both such counterparts taken together shall constitute one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including .pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
20.UNDERSTANDING OF EXECUTIVE; CONSULTATION WITH COUNSEL. Executive represents to Company that Executive has read this Agreement in its entirety, that Executive understands it and that Executive has entered into it voluntarily. Executive hereby further acknowledges and represents that Executive has consulted with independent legal counsel regarding Executive’s rights and obligations under this Agreement and that Executive fully understands the terms and conditions contained herein, including without limitation the obligations, restrictions, and provisions set forth in Section 5, 6, 9, and 10 of this Agreement.
[signatures follow]

14




IN WITNESS WHEREOF, the parties intending to be legally bound have executed this Executive Employment Agreement as of the date first set forth above.
                          
PETMED EXPRESS, INC.
                          By: /s/ Leslie C. G. Campbell
                              Leslie C. G. Campbell,
                            Chair of the Board of Directors
    
        
EXECUTIVE

By: /s/ Sandra Campos
    Sandra Campos, individually


15

EX-99.1 4 pets-20240429xexx991pressr.htm EX-99.1 Document

EXHIBIT 99.1
PetMed Express, Inc. Names Sandra Campos as new Chief Executive Officer and President

•Sandra Campos, retail E-commerce veteran, becomes CEO and President, effective immediately, after spending the past year serving on the Company’s Board of Directors and remains on the Board
•Ms. Campos brings a deep understanding of the industry and company; focusing on unlocking shareholder value through a renewed emphasis on customer experience, operational excellence and digital marketing transformation

DELRAY BEACH, Fla., April 29, 2024 – PetMed Express, Inc. ("PetMeds®" or the “Company”) (NASDAQ: PETS), Your Trusted Pet Health Expert, today announced that the Board of Directors has appointed veteran retail executive and current PetMeds board member Sandra Campos as President and CEO, effective immediately. Ms. Campos also remains on the Board of Directors. Matt Hulett has stepped down as Chief Executive Officer and President and as a Director of the Company and will work with Ms. Campos to facilitate a smooth transition of leadership responsibilities before departing the Company on May 10, 2024. He will remain an advisor to the Company through August 2024.

Campos, a globally recognized, seasoned executive in consumer retail with over 25 years of leadership, previously served as CEO of Diane von Furstenberg and President of a portfolio of global brands including Juicy Couture, BCBG, Bebe and Herve Leger. Ms. Campos’ focus on the ever-evolving consumer landscape has transformed businesses for growth across digital and physical retail through technology, innovative marketing direct to the consumer, and supply chain diversification.

“Sandra is ideally suited to lead PetMeds’ next chapter and the Board is confident in her ability to drive sustainable profitable growth and shareholder value,” said Leslie C. G. Campbell, Chairman of the Board. “She is a proven leader and innovative marketer with a strategic, customer-centric mindset and passion for the pet wellness industry. Her extensive experience in building brands, evolving technology platforms, and driving digital transformations, along with a strong track record of operational excellence, will be instrumental in shaping our future success.”

Speaking on the new role, Ms. Campos said, “I am honored to be joining the PetMeds team as President and CEO and bringing my deep-rooted experience and unwavering passion for the industry to PetMeds at this pivotal time. Based on my background, industry knowledge and understanding of the Company, I am confident that this transition will unfold seamlessly, benefiting all stakeholders of PetMeds.” Campos continued, “In partnership with this dedicated Board, we will continue to focus on harnessing the collective potential of both the PetMeds and PetCareRx teams to propel growth, foster exceptional experiences for our customers and employees and drive significant value for our shareholders. I look forward to talking with analysts and shareholders after our earnings call next month,” Campos concluded.

"It has been a privilege to lead this Company and I am confident that Sandra's extensive experience and leadership skills position her to guide PetMeds into a promising future,” stated Mr. Hulett.

Ms. Campbell added, “The Board thanks Matt for his contributions over the past two and a half years and wishes him all the best in his future endeavors.”


About Sandra Campos

A globally recognized leader in consumer retail, Sandra Campos is the former Chief Executive Officer of Diane von Furstenberg and former President of a $1 billion portfolio of brands including Juicy Couture, BCBG, Bebe and Herve Leger. Before that time, Ms. Campos also held leadership roles with apparel companies Polo Ralph Lauren and Nautica International. Ms. Campos’ focus on the ever-evolving consumer landscape has transformed businesses for growth across digital and physical retail through technology, innovative marketing direct to the consumer, and supply chain diversification. Balancing her career between corporate roles and entrepreneurial ventures, she also co-founded the first celebrity brand management company for Selena Gomez, which included global licenses across fourteen categories. Her breadth of knowledge across the retail ecosystem ranges from software, product development, sourcing, and international distributor/franchise partnerships, to digital marketing and ecommerce.



Ms. Campos serves as a Director of Big Lots Stores, and is a regular CNBC contributor speaking on retail trends and consumer news. She has been recognized in the top 100 Latina Leaders and as a Top Woman in Retail.

ABOUT PETMEDS

Founded in 1996, PetMeds is Your Trusted Pet Health Expert, delivering pet medications, food, health services and other products direct to the consumer at PetMeds.com and PetCareRX.com and through its toll-free number (1-800-PetMeds). PetMeds aims to be the most trusted pet health expert by providing incredible care and services that are affordable to the broadest group of pet parents--because every pet deserves to live a long, happy, healthy life. For more information, please visit www.petmeds.com.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. Words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and other similar words and expressions are intended to signify forward-looking statements. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain and are subject to various risks and uncertainties, including the Company’s ability to meet the objectives in its business plan. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission (“SEC”), including, but not limited to, the Company's Annual Report on Form 10-K/A for the year ended March 31, 2023, as well as other subsequent filings on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.


PETMEDS INVESTOR RELATIONS CONTACT
MZ North America
Brian M. Prenoveau, CFA
investor@petmeds.com
(561)489-5315